These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

572 related items for PubMed ID: 27453079

  • 21. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB, Nordbrock E, Adjei AL, Childress A, Kupper RJ, Greenhill L.
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [Abstract] [Full Text] [Related]

  • 22. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH, López FA, Vince BD, Turnbow JM, Farrand K, Lyne A, Wigal SB, Roth T.
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
    [Abstract] [Full Text] [Related]

  • 23. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.
    Pharmacoeconomics; 2012 Aug 01; 30(8):e1-15. PubMed ID: 22788263
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 01; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 25. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Faraone SV, McBurnett K, Sallee FR, Steeber J, López FA.
    Clin Ther; 2013 Nov 01; 35(11):1778-93. PubMed ID: 24139092
    [Abstract] [Full Text] [Related]

  • 26. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G, Zeni C, Genro JP, Guimarães AP, Roman T, Hutz MH, Rohde LA.
    Arch Gen Psychiatry; 2007 Feb 01; 64(2):218-24. PubMed ID: 17283289
    [Abstract] [Full Text] [Related]

  • 27. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J, SPD503 STUDY GROUP.
    J Am Acad Child Adolesc Psychiatry; 2009 Feb 01; 48(2):155-65. PubMed ID: 19106767
    [Abstract] [Full Text] [Related]

  • 28. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC, Kollins SH, Foehl HC, Newcorn JH, Mattingly G, Kupper RJ, Adjei AL.
    J Child Adolesc Psychopharmacol; 2020 Mar 01; 30(2):58-68. PubMed ID: 32125903
    [Abstract] [Full Text] [Related]

  • 29. Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy.
    Schneider G, Banaschewski T, Feldman BL, Gustafsson PA, Murphy B, Reynolds M, Coghill DR, Spalding WM.
    J Child Adolesc Psychopharmacol; 2019 May 01; 29(4):285-304. PubMed ID: 30942617
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
    Childress A, Hoo-Cardiel A, Lang P.
    Expert Opin Pharmacother; 2020 Mar 01; 21(4):417-426. PubMed ID: 31971448
    [Abstract] [Full Text] [Related]

  • 31. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD.
    Kollins SH, Jain R, Brams M, Segal S, Findling RL, Wigal SB, Khayrallah M.
    Pediatrics; 2011 Jun 01; 127(6):e1406-13. PubMed ID: 21555501
    [Abstract] [Full Text] [Related]

  • 32. α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
    Harstad E, Shults J, Barbaresi W, Bax A, Cacia J, Deavenport-Saman A, Friedman S, LaRosa A, Loe IM, Mittal S, Tulio S, Vanderbilt D, Blum NJ.
    JAMA; 2021 May 25; 325(20):2067-2075. PubMed ID: 33946100
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder.
    Sallee FR, Kollins SH, Wigal TL.
    J Child Adolesc Psychopharmacol; 2012 Jun 25; 22(3):206-14. PubMed ID: 22612526
    [Abstract] [Full Text] [Related]

  • 34. Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Huss M, McBurnett K, Cutler AJ, Hervás A, Bliss C, Gao J, Dirks B, Newcorn JH.
    Eur Neuropsychopharmacol; 2019 Mar 25; 29(3):432-443. PubMed ID: 30064718
    [Abstract] [Full Text] [Related]

  • 35. Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study.
    Butterfield ME, Saal J, Young B, Young JL.
    Psychiatry Res; 2016 Feb 28; 236():136-141. PubMed ID: 26730446
    [Abstract] [Full Text] [Related]

  • 36. Guanfacine extended-release: in attention deficit hyperactivity disorder.
    Muir VJ, Perry CM.
    Drugs; 2010 Sep 10; 70(13):1693-702. PubMed ID: 20731476
    [Abstract] [Full Text] [Related]

  • 37. Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study.
    Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H.
    BMC Psychiatry; 2020 Oct 02; 20(1):485. PubMed ID: 33008345
    [Abstract] [Full Text] [Related]

  • 38. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.
    Jain R, Segal S, Kollins SH, Khayrallah M.
    J Am Acad Child Adolesc Psychiatry; 2011 Feb 02; 50(2):171-9. PubMed ID: 21241954
    [Abstract] [Full Text] [Related]

  • 39. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N, SPD503 Study Group.
    Pediatrics; 2008 Jan 02; 121(1):e73-84. PubMed ID: 18166547
    [Abstract] [Full Text] [Related]

  • 40. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N, Koh T, Tominaga Y, Saito Y, Kashimoto Y, Matsumura T.
    World J Biol Psychiatry; 2014 Aug 02; 15(6):488-98. PubMed ID: 24456065
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.